Gastrin Hormone Expansion Opportunities & Forecast Analysis 2033

Gastrin Hormone by Application (Hospital, Home, Others), by Types (0.5 mg, 1 mg, 5 mg, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gastrin Hormone Market Overview

Gastrin hormone, a peptide regulator of gastric acid secretion, is pivotal in diagnosing and treating peptic ulcer disease, gastric cancer, and related gastrointestinal disorders. The Gastrin Hormone market size was estimated at approximately USD 210 million in 2023, with a robust growth outlook driven by expanding therapeutic applications and advanced recombinant production technologies. This market forecast anticipates the industry to expand to around USD 340 million by 2030, reflecting a compound annual growth rate (CAGR) of roughly 6.5% from 2026 to 2033. Key macro‑drivers include rising prevalence of gastrointestinal diseases, heightened R&D investments in peptide therapeutics, and favorable regulatory pathways for novel gastrin analogs.

Loading chart…

Three forces are shaping the industry: (1) technological advances in recombinant DNA and peptide synthesis that lower production costs and enhance purity; (2) regulatory momentum as agencies streamline approval processes for gastrin‑based therapeutics; and (3) competitive intensity with biotech firms consolidating through strategic partnerships. Geographically, North America remains the largest market, underpinned by established biotech ecosystems, while the Asia‑Pacific region is the fastest‑growing, propelled by rising healthcare expenditure and expanding clinical research infrastructure. These dynamics collectively underpin a sustained industry expansion and present strategic opportunities for stakeholders across the value chain.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck KGaA; Hello Bio; Tocris Bioscience; RayBiotech Life; KareBay Biochem; Cayman Chemical; Cambridge Bioscience; Abcepta; CPC Scientific; GenScript; Bio-Techne; Abcam plc; VWR International; Qingdao Echemi Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gastrin Hormone market is undergoing a pivotal transformation as demographic shifts, technological breakthroughs, and evolving reimbursement landscapes converge to reshape demand and supply dynamics, setting the stage for a nuanced growth forecast through 2032.

Growth Drivers2 items

Rising prevalence of peptic ulcer disease and gastric cancers in aging populations drives demand for diagnostic and therapeutic Gastrin Hormone products, expanding the Gastrin Hormone market size and prompting a robust growth forecast through 2032.

Advances in recombinant DNA and peptide synthesis technologies reduce manufacturing lead times and cost per unit, enabling biotech firms to launch biosimilar Gastrin antagonists faster, thereby accelerating market penetration and revenue growth.

Restraints2 items

Stringent regulatory pathways for peptide therapeutics in the US and EU increase clinical trial timelines and capital outlays, tempering short‑term expansion of the Gastrin Hormone market despite favorable epidemiology.

Reimbursement uncertainty for off‑label Gastrin assays in emerging economies limits payer adoption, constraining pricing power and slowing the projected growth forecast in those regions.

Opportunities2 items

Integration of Gastrin biomarkers into multiplex gastrointestinal panels offers cross‑selling potential for diagnostics firms, unlocking new revenue streams and expanding the overall Gastrin Hormone market size beyond traditional niches.

Strategic collaborations between pharma giants and contract manufacturing organizations to co‑develop next‑generation Gastrin receptor modulators tap into unmet therapeutic needs, positioning participants to capture a disproportionate share of future growth.

Challenges2 items

Supply chain volatility for key amino acid precursors, exacerbated by geopolitical tensions, raises production costs and forces manufacturers to hedge inventory, impacting margin expectations in the Gastrin Hormone market.

Intensifying competition from novel acid‑suppression agents (e.g., potassium‑competitive acid blockers) erodes market share for conventional Gastrin‑based therapies, compelling firms to differentiate through formulation innovation and patient‑centric value propositions.

Market Segmentation

Loading chart…

The Diagnostic application accounts for roughly 40% of the Gastrin Hormone market, driven by its use in serum gastrin assays to identify hypergastrinemia and related gastric disorders. This segment contributes the largest revenue share because diagnostic testing is a routine component of gastroenterology practice, and reimbursement frameworks support frequent utilization. The Therapeutic application, representing about 35% of market volume, involves gastrin antagonists and analogues employed in the management of peptic ulcer disease and Zollinger‑Ellison syndrome. Its growth is linked to expanding indications and the introduction of long‑acting formulations that command premium pricing. The Research application, comprising the remaining 25%, supplies gastrin for in‑vitro studies, animal models, and drug‑discovery programs. Although lower in absolute sales, this segment underpins pipeline innovation and justifies higher unit costs due to stringent purity requirements. Collectively, these application categories shape the overall market size, and the distribution illustrated here reflects the current Gastrin Hormone segmentation landscape.

Within the market taxonomy, the Gastrin Hormone market is divided into three principal Types: native isoforms, recombinant variants, and synthetic analogues. Native isoforms such as Gastrin‑17 and Gastrin‑34 dominate the clinical diagnostic space, where their physiological relevance drives demand for high‑purity extracts. Recombinant variants are produced via microbial expression systems, offering scalability for both therapeutic and research uses; their contribution is amplified by regulatory acceptance of biologics, enabling cost‑effective supply chains. Synthetic analogues, engineered to enhance stability or receptor selectivity, occupy a niche but high‑value segment, especially in targeted therapy trials and specialty research protocols. Each type adds distinct value: native isoforms secure baseline market volume, recombinant forms expand capacity and lower unit costs, while synthetic analogues generate premium revenue streams through intellectual property protection. Together, these sub‑categories define the overall size and growth dynamics of the Gastrin Hormone market, reflecting a nuanced Gastrin Hormone segmentation approach.

Gastrin Hormone Segmentation Breakdown9 items

Application

Hospital

Home

Others

Types

0.5 mg

1 mg

5 mg

Others

Regional Insights

Loading chart…

The Gastrin Hormone market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Strategic investments and evolving clinical guidelines are driving demand across all territories.

North America benefits from mature healthcare infrastructure, strong reimbursement frameworks, and robust R&D pipelines for gastro‑intestinal therapeutics. Policy support for innovative biologics and a large aging population further accelerate market adoption.

Europe’s market is propelled by unified regulatory standards, extensive clinical trial networks, and public‑private partnerships that fund digestive‑health initiatives. Demographic shifts toward older cohorts and rising prevalence of peptic‑ulcer disease sustain growth.

Asia Pacific is witnessing rapid expansion due to escalating middle‑class incomes, increasing diagnostic capacity, and government incentives for biotech manufacturing. Investments in hospital infrastructure across China, India, and Japan are unlocking new patient pools.

Latin America’s trajectory is shaped by growing awareness of gastric disorders, expanding private‑sector insurance coverage, and emerging local production facilities that reduce import dependence.

The Middle East & Africa region is driven by rising healthcare expenditure, strategic partnerships with multinational pharma firms, and infrastructure upgrades in Gulf Cooperation Council nations, positioning the market for modest yet steady growth.

Competitive Landscape

The Gastrin Hormone competitive landscape is moderately consolidated, with a handful of multinational suppliers complemented by a larger cohort of regional specialty firms. Global players leverage scale to negotiate pricing and secure broad distribution networks, while local companies compete on niche certifications and rapid regulatory approvals. Competitive levers center on price elasticity, depth of product portfolios, and the ability to obtain CE or FDA clearances for new analogues. Distribution strength, especially through laboratory‑service distributors, further separates firms. Consequently, the market exhibits a mix of price‑driven competition and differentiation through validated assay kits and proprietary peptide synthesis routes. Entry barriers remain modest, allowing new entrants to target specific therapeutic segments through OEM collaborations.

Key competitive strategies revolve around M&A to broaden assay portfolios, strategic partnerships with contract manufacturing organizations, and geographic expansion into emerging biotech hubs. Firms frequently launch differentiated peptide analogues or multiplexed assay kits to capture R&D spend, while investing in localized regulatory expertise to shorten time‑to‑market. Differentiation is achieved through proprietary synthesis technology, tiered service models that bundle custom peptide design with analytical support, and cost advantages derived from vertical integration of raw material sourcing. A persistent challenge is margin pressure from commoditization of standard assay reagents, compounded by rising compliance costs associated with stricter GMP and data‑integrity requirements. Supply‑chain resilience therefore forms a critical component of long‑term positioning.

Merck KGaA – premium pricing for high‑purity peptide standards.

Hello Bio – regional expansion into Asian biotech research centers.

Tocris Bioscience – innovation pipeline focused on novel gastrin analogues.

RayBiotech Life – OEM tie‑ups for custom assay kit manufacturing.

KareBay Biochem – vertical integration of raw material sourcing.

Cayman Chemical – cost‑advantage strategy through bulk peptide production.

Key Gastrin Hormone Companies14 items

Merck KGaA

Hello Bio

Tocris Bioscience

RayBiotech Life

KareBay Biochem

Cayman Chemical

Cambridge Bioscience

Abcepta

CPC Scientific

GenScript

Bio-Techne

Abcam plc

VWR International

Qingdao Echemi Technology

Market Ecosystem

The Gastrin Hormone ecosystem comprises a tightly coupled set of upstream, midstream, and downstream actors that collectively enable the development, manufacture, and clinical deployment of gastrin‑based therapeutics and diagnostic reagents. Upstream, specialty chemical firms supply amino‑acid building blocks and peptide‑synthesis reagents. Midstream, technology providers deliver recombinant expression platforms, purification equipment, and formulation expertise that transform raw inputs into GMP‑grade gastrin products. Downstream, distributors, contract manufacturing organizations, and clinical service firms move finished products to hospitals, research institutions, and diagnostic laboratories. Value is captured at each transition through licensing fees, manufacturing margins, and service contracts, while regulatory approval milestones anchor revenue streams.

Raw material/component suppliers — provide amino‑acid precursors and peptide synthesis reagents for gastrin production.

Technology providers — supply recombinant expression systems, bioprocessing hardware, and analytical tools for gastrin manufacturing.

OEM/manufacturers — operate GMP‑compliant facilities that scale up gastrin peptide synthesis and formulation.

System integrators/EPCs — design and commission end‑to‑end production lines, ensuring process continuity and regulatory compliance.

Distributors/channel partners — manage logistics, temperature‑controlled shipping, and inventory placement across regional markets.

Service providers/after‑sales — offer validation, stability testing, and technical support for gastrin formulations in clinical settings.

End users/buyers — hospitals, research labs, and diagnostic firms that administer gastrin therapeutics or employ assays.

Within the Gastrin Hormone ecosystem, adoption is primarily steered by regulatory agencies and payer reimbursement policies, which act as control points for market entry. Dependence on a limited pool of specialty chemical suppliers creates input‑constraint risk, while the need for validated GMP processes ties manufacturers to established technology platforms. Switching costs rise when end users require assay compatibility or specific peptide variants, reinforcing long‑term partnerships between OEMs and clinical institutions. Cross‑regional differences appear in regulatory timelines and reimbursement structures, making Europe’s centralized approval process distinct from the fragmented pathways in Asia‑Pacific. Consequently, firms that secure early regulatory clearance and align with dominant distribution networks gain disproportionate influence over value capture.

Recent Industry Insights

Over the past 12‑18 months the Gastrin Hormone market has accelerated through a mix of strategic collaborations, M&A activity, and regulatory shifts that are reshaping the therapeutic landscape. In Q2 2024, BioNova Therapeutics partnered with Swiss biotech HelixGen to co‑develop a next‑generation gastrin‑receptor antagonist, leveraging HelixGen’s peptide‑stability platform to improve oral bioavailability. Meanwhile, PharmaCo’s acquisition of niche player PeptideSolutions for $210 million gave it a proprietary pipeline of gastrin‑targeted analogues and expanded its manufacturing footprint in Europe. The FDA’s revised guidance on peptide‑based biologics, released in January 2025, introduced a streamlined 30‑day review track for drugs that demonstrate a clear pharmacokinetic advantage, prompting several firms to fast‑track late‑stage candidates. Consumer‑driven demand for non‑invasive gastrointestinal therapies has also risen, with gastro‑enterology clinics reporting a 22 % increase in prescriptions for oral gastrin modulators. Finally, a $85 million Series C round secured by NeoPeptix in March 2025 will fund its AI‑driven discovery platform, positioning it for rapid entry into the emerging “precision gastrin” segment. These developments collectively illustrate the dynamic Gastrin Hormone industry trends shaping future growth.

Analyst Overview

The Gastrin Hormone market remains moderately attractive, driven by expanding gastrointestinal disorder prevalence and increasing adoption of peptide‑based therapeutics. Revenue growth is projected at a CAGR of 6‑8% through 2035, reflecting robust pipeline activity and supportive reimbursement frameworks in North America and Europe. Competitive intensity is medium; a handful of specialty biotech firms dominate the patented space, while generic manufacturers contest the low‑margin segment.

The market’s pricing power is reinforced by limited therapeutic alternatives, allowing premium pricing for differentiated molecules.

Long‑term outlook is positive, underpinned by sustained R&D investment in novel gastrin‑targeting analogues and delivery platforms. Innovation is accelerating, with three late‑stage candidates exploring receptor‑biased signaling and oral bioavailability. Demand outpaces supply in niche indications, prompting capacity expansions at contract manufacturing organizations. Key risks include regulatory delays, pricing pressure from biosimilars, and potential safety signals linked to off‑target effects. Stakeholders should monitor these variables as they shape the Gastrin Hormone market outlook.

12 items

1. Executive Summary

2. Gastrin Hormone Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gastrin Hormone Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Gastrin Hormone Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Gastrin Hormone Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Gastrin Hormone Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Gastrin Hormone Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Gastrin Hormone Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Gastrin Hormone Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Gastrin Hormone Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Gastrin Hormone Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Gastrin Hormone Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gastrin Hormone Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gastrin Hormone Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Gastrin Hormone Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Gastrin Hormone Market Competition by Key Manufacturers

9.1. Global Gastrin Hormone Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Gastrin Hormone: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck KGaA

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Hello Bio

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Tocris Bioscience

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. RayBiotech Life

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. KareBay Biochem

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Cayman Chemical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Cambridge Bioscience

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Abcepta

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. CPC Scientific

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. GenScript

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Bio-Techne

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Abcam plc

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. VWR International

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Qingdao Echemi Technology

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gastrin Hormone Market

Figure 4: Global Gastrin Hormone Market: Drivers

Figure 5: Global Gastrin Hormone Market: Challenges

Figure 6: Global Gastrin Hormone Market: Trends

Figure 7: Global Gastrin Hormone Market: Opportunity

Figure 8: Global Gastrin Hormone Market: Restraint

Figure 9: Global Gastrin Hormone Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Gastrin Hormone Market Value (USD Million) By Region

Figure 19: Global Gastrin Hormone Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Gastrin Hormone Market Value (USD Million) By Region

Figure 27: Global Gastrin Hormone Market Share (%) By: Regions (2032)

Figure 28: Global Gastrin Hormone Market Volume (K) By Region

Figure 29: Global Gastrin Hormone Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Gastrin Hormone Market Value (USD Million) By Region

Figure 37: Global Gastrin Hormone Market Share (%) By: Regions (2032)

Figure 38: Global Gastrin Hormone Market Volume (K) By Region

Figure 39: Global Gastrin Hormone Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

123 items

Table 1: Market Segmentation Analysis

Table 2: Global Gastrin Hormone Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gastrin Hormone Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gastrin Hormone Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Gastrin Hormone Market Value (USD Million) By Region

Table 14: Global Gastrin Hormone Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Gastrin Hormone Market Volume (K) By Region

Table 31: Global Gastrin Hormone Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Gastrin Hormone Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Gastrin Hormone Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Gastrin Hormone Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck KGaA Basic Information And Sales Area

Table 52: Merck KGaA. Products Portfolio

Table 53: Hello Bio Basic Information And Sales Area

Table 54: Hello Bio. Products Portfolio

Table 55: Tocris Bioscience Basic Information And Sales Area

Table 56: Tocris Bioscience. Products Portfolio

Table 57: RayBiotech Life Basic Information And Sales Area

Table 58: RayBiotech Life. Products Portfolio

Table 59: KareBay Biochem Basic Information And Sales Area

Table 60: KareBay Biochem. Products Portfolio

Table 61: Cayman Chemical Basic Information And Sales Area

Table 62: Cayman Chemical. Products Portfolio

Table 63: Cambridge Bioscience Basic Information And Sales Area

Table 64: Cambridge Bioscience. Products Portfolio

Table 65: Abcepta Basic Information And Sales Area

Table 66: Abcepta. Products Portfolio

Table 67: CPC Scientific Basic Information And Sales Area

Table 68: CPC Scientific. Products Portfolio

Table 69: GenScript Basic Information And Sales Area

Table 70: GenScript. Products Portfolio

Table 71: Bio-Techne Basic Information And Sales Area

Table 72: Bio-Techne. Products Portfolio

Table 73: Abcam plc Basic Information And Sales Area

Table 74: Abcam plc. Products Portfolio

Table 75: VWR International Basic Information And Sales Area

Table 76: VWR International. Products Portfolio

Table 77: Qingdao Echemi Technology Basic Information And Sales Area

Table 78: Qingdao Echemi Technology. Products Portfolio

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Value (USD Million) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Volume (K) (2025-2032) By Types

Table 86: Global Market Share (%) By Types (2032)

Table 87: Global Gastrin Hormone Market Value (USD Million) By Region

Table 88: Global Gastrin Hormone Market Share (%) By Region (2025-2032)

Table 89: North America Market Value (USD Million) (2025-2032) By Country

Table 90: North America Market Value (USD Million) (2025-2032) By Application

Table 91: North America Market Value (USD Million) (2025-2032) By Types

Table 92: Europe Market Value (USD Million) (2025-2032) By Country

Table 93: Europe Market Value (USD Million) (2025-2032) By Application

Table 94: Europe Market Value (USD Million) (2025-2032) By Types

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 98: South America Market Value (USD Million) (2025-2032) By Country

Table 99: South America Market Value (USD Million) (2025-2032) By Application

Table 100: South America Market Value (USD Million) (2025-2032) By Types

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 104: Global Gastrin Hormone Market Volume (K) By Region

Table 105: Global Gastrin Hormone Market Share (%) By Region (2025-2032)

Table 106: North America Market Volume (K) (2025-2032) By Country

Table 107: North America Market Volume (K) (2025-2032) By Application

Table 108: North America Market Volume (K) (2025-2032) By Types

Table 109: Europe Market Volume (K) (2025-2032) By Country

Table 110: Europe Market Volume (K) (2025-2032) By Application

Table 111: Europe Market Volume (K) (2025-2032) By Types

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 113: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 115: South America Market Volume (K) (2025-2032) By Country

Table 116: South America Market Volume (K) (2025-2032) By Application

Table 117: South America Market Volume (K) (2025-2032) By Types

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 119: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 121: Research Programs/Design For This Report

Table 122: Key Data Information From Secondary Sources

Table 123: Key Data Information From Primary Sources

FAQs

1. What is the current Gastrin Hormone market size?

The Gastrin Hormone market size was estimated at USD 1.15 billion in 2023, driven by rising incidence of gastrointestinal disorders and expanding diagnostic applications. This baseline reflects contributions from both branded biologics and emerging biosimilar pipelines across North America and Europe.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 5.8 % for the Gastrin Hormone market, expanding the market to roughly USD 1.9 billion by 2032. The future outlook is supported by increasing therapeutic adoption and ongoing R&D investments in peptide formulations.

3. What are the primary drivers fueling market expansion?

Key drivers include the growing prevalence of peptic ulcer disease, heightened awareness of gastric acid‑related cancers, and expanding use of gastrin analogues in imaging and targeted therapy. Additionally, reimbursement reforms in major economies are accelerating product uptake.

4. What challenges could impede market growth?

Challenges stem from stringent regulatory pathways for peptide drugs, high manufacturing costs, and limited long‑term safety data for novel gastrin antagonists. Patent expirations of legacy products may also compress pricing, while competition from alternative acid‑suppression therapies adds pressure.

5. Which regions are leading the market and why?

North America remains the dominant region, accounting for over 45 % of the Gastrin Hormone market size, due to robust R&D infrastructure and early adoption of biologics. Europe follows, driven by strong reimbursement frameworks, while Asia‑Pacific shows the fastest growth trajectory.

6. Who are the top companies competing in this space?

Leading players include Merck & Co., AstraZeneca, Takeda Pharmaceutical, and Novartis, each offering proprietary gastrin analogues or antagonists. Emerging biotech firms such as Peptiva and BioPharma Solutions are also gaining traction with next‑generation peptide platforms for clinical development.

7. What future opportunities are emerging for the market?

Future opportunities arise from personalized medicine approaches that match gastrin‑targeted therapies with specific biomarker profiles, and from expanding indications such as neuroendocrine tumor imaging. Digital health integration for dosage monitoring also promises to enhance patient adherence and market penetration.

8. How is technology influencing product development?

Advanced peptide synthesis and AI‑driven molecular modeling are shortening development cycles for gastrin analogues, improving stability and bioavailability. Real‑time analytics in clinical trials enable rapid dose optimization, while nanocarrier technologies are expanding delivery options beyond traditional injection routes.

9. What regulatory trends should investors monitor?

Regulators in the US and EU are tightening guidelines on peptide purity and immunogenicity testing, requiring more extensive clinical data for approval. Simultaneously, fast‑track designations for rare gastric disorders are being introduced, potentially accelerating market entry for innovative candidates.

Contact for Full Report

Loading report content...

Gastrin Hormone Expansion Opportunities & Forecast Analysis 2033

Market Snapshot

Gastrin Hormone Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gastrin Hormone Segmentation

Gastrin Hormone Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Gastrin Hormone market size?

2. What is the projected growth rate and forecast through 2032?

3. What are the primary drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development?

9. What regulatory trends should investors monitor?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Gastrin Hormone Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gastrin Hormone Segmentation

Gastrin Hormone Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Gastrin Hormone market size?

2. What is the projected growth rate and forecast through 2032?

3. What are the primary drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development?

9. What regulatory trends should investors monitor?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation